Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Skin Diseases, Papulosquamous 1Skin Diseases 1Sarcoma, Synovial 1Sarcoma 1Psoriasis 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Plaque, Amyloid 1Myelodysplastic Syndromes 1Lymphoma, Follicular 1Lymphoma 1Liposarcoma, Myxoid 1Leukemia, Myeloid, Acute 1Leukemia, Biphenotypic, Acute 1Leiomyosarcoma 1Histiocytoma, Malignant Fibrous 1Graft vs Host Disease 1Chondrosarcoma 1Bronchiolitis Obliterans Syndrome 1Arthritis, Rheumatoid 1Adenoma, Liver Cell 1

Interventions

Cyclophosphamide 447Rituximab 406Etoposide 225Vincristine 217Doxorubicin 204Filgrastim 201Prednisone 178Cytarabine 160Radiotherapy 152fludarabine phosphate 148Methotrexate 137Peripheral Blood Stem Cell Transplantation 130Melphalan 128fludarabine 116Busulfan 101Dexamethasone 93Tacrolimus 76Carmustine 74Granulocyte Colony-Stimulating Factor 73Mycophenolic Acid 72Gemcitabine 66Bortezomib 65Antilymphocyte Serum 65Whole-Body Irradiation 63Bendamustine Hydrochloride 63Lenalidomide 62Cyclosporine 62Ifosfamide 58sargramostim 51Methylprednisolone 49

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma × baricitinib × Clear all
NCT06475820 2024-08-23

Preventing of GVHD With Post-transplantation Cyclophosphamide, Abatacept, Vedolizumab and Baricitinib at Children and Young Adults With Hemoblastosis

Federal Research Institute of Pediatric Hematology, Oncology and Immunology

Phase 2/3 Active not recruiting
150 enrolled
LymphoidMyeloidOther hematologic neoplasm

Graft vs Host Disease, Lymphoma, Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡